CN103690567A - 一种五倍子的乙酸乙酯提取物及其制备、检测方法和用途 - Google Patents
一种五倍子的乙酸乙酯提取物及其制备、检测方法和用途 Download PDFInfo
- Publication number
- CN103690567A CN103690567A CN201310680435.0A CN201310680435A CN103690567A CN 103690567 A CN103690567 A CN 103690567A CN 201310680435 A CN201310680435 A CN 201310680435A CN 103690567 A CN103690567 A CN 103690567A
- Authority
- CN
- China
- Prior art keywords
- ethyl acetate
- acetate extract
- gallic
- extract
- petroleum ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002024 ethyl acetate extract Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000001514 detection method Methods 0.000 title abstract description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000003208 petroleum Substances 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 238000012360 testing method Methods 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000001819 mass spectrum Methods 0.000 claims description 8
- 229920001864 tannin Polymers 0.000 claims description 8
- 235000018553 tannin Nutrition 0.000 claims description 8
- 239000001648 tannin Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 238000011026 diafiltration Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- OTEKOJQFKOIXMU-UHFFFAOYSA-N 1,4-bis(trichloromethyl)benzene Chemical compound ClC(Cl)(Cl)C1=CC=C(C(Cl)(Cl)Cl)C=C1 OTEKOJQFKOIXMU-UHFFFAOYSA-N 0.000 claims description 4
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 4
- 229920000296 Glucogallin Polymers 0.000 claims description 4
- 229920000864 Punicalin Polymers 0.000 claims description 4
- 150000001272 acylglucoses Chemical class 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- DCYOADKBABEMIQ-OWMUPTOHSA-N myricitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1=O DCYOADKBABEMIQ-OWMUPTOHSA-N 0.000 claims description 4
- DCYOADKBABEMIQ-FLCVNNLFSA-N myricitrin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1=O DCYOADKBABEMIQ-FLCVNNLFSA-N 0.000 claims description 4
- IQHIEHIKNWLKFB-ITTSEVFZSA-N pumcalin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1OC(=O)C1=CC(O)=C(O)C(O)=C11)O)O)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(OC3=O)C4=C2C(=O)OC2=C4C3=C1C(O)=C2O IQHIEHIKNWLKFB-ITTSEVFZSA-N 0.000 claims description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims description 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 4
- 235000012141 vanillin Nutrition 0.000 claims description 4
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 4
- 239000006199 nebulizer Substances 0.000 claims description 3
- 239000003643 water by type Substances 0.000 claims description 3
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 claims description 2
- MVCIFQBXXSMTQD-UHFFFAOYSA-N 3,5-dicaffeoylquinic acid Natural products Cc1ccc(C=CC(=O)OC2CC(O)(CC(OC(=O)C=Cc3ccc(O)c(O)c3)C2O)C(=O)O)cc1C MVCIFQBXXSMTQD-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000010992 reflux Methods 0.000 abstract description 7
- 239000006228 supernatant Substances 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 238000004821 distillation Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 27
- 239000000243 solution Substances 0.000 description 14
- 239000000843 powder Substances 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000003810 ethyl acetate extraction Methods 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 3
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- MBNNRMVOTYNNIX-HBEKLPNASA-N (3R,5R)-3,5-bis[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@](C1O)(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)(C(=O)O)O)O MBNNRMVOTYNNIX-HBEKLPNASA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 229920002079 Ellagic acid Polymers 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 2
- 241001516602 Schlechtendalia chinensis Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229960002852 ellagic acid Drugs 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 241000463291 Elga Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000003043 HTRF KinEASE-TK Methods 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 241001206332 Rhus potaninii Species 0.000 description 1
- 241001206339 Rhus punjabensis Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical group [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种五倍子的乙酸乙酯提取物及其制备、检测方法和用途,所述乙酸乙酯提取物由以下方法制备:五倍子,用石油醚浸泡,石油醚渗滤,回收残渣,挥干残渣中的石油醚,然后用乙醇回流提取,提取液浓缩至无醇味,然后用与浓缩液等体积的乙酸乙酯萃取,收集上层清液,蒸干,即得乙酸乙酯提取物。经过体外试验,发现本发明提供的五倍子的乙酸乙酯提取物可抑制EGFR活性,效果明显。
Description
[技术领域]
本发明涉及五倍子提取物及其制备、检测方法和应用,具体涉一种五倍子的乙酸乙酯提取物及其制备、检测方法和应用。
[背景技术]
表皮生长因子受体(EGFR)是EGFR酪氨酸激酶家族的成员之一,它包含有一个细胞外配体结合区、单一的跨膜区和一个含酪氨酸激酶结构的胞内区。EGFR与配体结合导致重要的构象变化,暴露受体中的二聚环结构,引发自身磷酸化,转导下游信号,调节细胞的增殖、凋亡、迁移、存活和一系列复杂的过程。EGRF在肿瘤细胞中常处于过度激活状态,使细胞周期失去调控,导致肿瘤细胞无限制生长,如神经胶质细胞瘤、乳腺癌、肺癌、卵巢癌、头颈部鳞癌、宫颈癌、食管癌、前列腺癌、肝癌、结肠癌、胃癌等。EGFR是目前抗肿瘤分子靶向治疗中,最成功也是最受关注的治疗靶点之一。FDA已批准两种靶向EGFR的小分子抑制剂,gefitinib(吉非替尼,易瑞沙)和erlotinib(厄洛替尼,特罗凯),随着时间的推移,在治疗中出现了耐药现象。而国内迄今为止,尚未有特异性EGFR抑制剂出现。
五倍子,漆树科植物盐肤木Rhus chinensis Mill.、青麸杨Rhus potaniniiMaxim.或红麸杨Rhus punjabensis Stew.var.sinica(Diels)Rehd.et wils.叶上的虫瘿,主要由五倍子蚜Melaphis chinensis(Bell)Baker寄生而形成。具有敛肺降火、涩肠止泻,敛汗,止血,收湿敛疮的作用。现代药理研究表明,五倍子具有以下药理作用:
1、抗菌作用:五倍子水提液能够减少牙龈卟啉菌内毒素诱导人单核细胞膜表面CD14的表达,有助于对牙周病的防治;五倍子水、乙醇提取物对变形链球菌Ingbritt株、茸毛链球菌均有较强作用。
2、抗病毒作用:五倍子煎剂具有很强的抑制HIV-Rt活性。
3、清除自由基和抗氧化作用:五倍子水煎剂有对老鼠抗衰老的作用;五倍子提取物能够抑制突变作用。
4、抗癌作用:五倍子提物对PGG具有抗癌作用;五倍子的醇浸提液具有治疗早期宫颈癌的作用。
迄今为止,尚未有关于五倍子的乙酸乙酯提取物及其相关应用于一直EGFR活性的报道。
[发明内容]
为了弥补现有技术尚无用五倍子乙酸乙酯提取物用于制造抑制EGFR活性的药物的空白,本发明提供了五倍子的乙酸乙酯提取物及其制备方法、检测方法和用途。
为实现上述目的,设计一种五倍子的乙酸乙酯提取物的方法,其特征在于该方法由以下步骤组成:
a.将五倍子加入到石油醚中浸泡12~48小时,每100g五倍子需要300~500毫升的石油醚,然后渗滤回收残渣;
b.所述的残渣用浓度为60%~90%的乙醇分2~3次提取,每100克残渣每次需要300~500毫升的乙醇,每次提取的时间是1~3小时,收集得到提取液;
c.所述的提取液进行浓缩得到浓缩液;
d.用与浓缩液等体积的乙酸乙酯对所述的浓缩液进行萃取,收集乙酸乙酯的萃取液;
e.蒸干所述的萃取液得到提取物。
每100g五倍子需要300毫升的石油醚浸泡。
所述的浸泡时间为18~36小时。
所述的乙醇浓度为70~90%。
所述的浸泡时间为24小时,每100克残渣每次需要300毫升的乙醇,所述的乙醇浓度为80%,所述的步骤(b)中的提取次数为2次。
本发明还包括一种用上述方法提取的五倍子的乙酸乙酯提取物,其特征在于该提取物含有主要成分:石榴皮鞣素,香草醛,六羟基二苯酰胺葡萄糖,鞣花单宁,杨梅苷,原儿茶素,五倍子单宁倍酰葡萄糖,五倍子单宁,鞣花酸,3,5-二咖啡酰奎宁酸,Monogalloyl-glucose。
本发明还包括一种药物制剂,由所述的五倍子的乙酸乙酯提取物和药学上可接受的载体组成。
所述制剂为片剂、胶囊、颗粒或丸剂。
所述药学上可接受的载体或稀释剂是指药学领域常规的药物载体,选自填充剂、粘合剂、崩解剂、润滑剂、助悬剂、润湿剂、溶剂、表面活性剂或矫味剂中的一种或几种。
所述填充剂选自淀粉、蔗糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素或葡萄糖等;
所述粘合剂选自纤维素衍生物、藻酸盐、淀粉、糊精、明胶或聚乙烯吡咯烷酮等;
所述崩解剂选自微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙基纤维素或交联羧甲基纤维素钠;
所述润滑剂选自硬脂酸、聚乙二醇、碳酸钙、碳酸氢钠、微粉硅胶、滑石粉或硬脂酸镁;
所述助悬剂选自微粉硅胶、蜂蜡、纤维素、固态聚乙二醇;
所述润湿剂选自甘油、吐温-80、乙氧基氢化蓖麻油或卵磷脂;
所述溶剂选自乙醇、液态聚乙二醇、异丙醇、吐温-80、甘油、丙二醇或植物油,所述植物油选自大豆油、蓖麻油、花生油、调和油等;
所述表面活性剂选自十二烷基苯磺酸钠、硬脂酸、聚氧乙烯-聚氧丙烯共聚物、脂肪酸山梨坦或聚山梨酯(吐温)等;
所述矫味剂选自阿斯巴甜、蔗糖素、香精、柠檬酸或糖精钠。
本发明的五倍子的乙酸乙酯提取物还可以用于制备抑制EGFR活性药物。
在抑制EGRF活性时,五倍子的乙酸乙酯提取物的用量(即每日服用量限定为0.1mg-3g)。
本发明还包括一种检测所述五倍子的乙酸乙酯提取物的方法,用超高效液相色谱-电喷雾串联质仪对所述五倍子提取物进行分析,以获得乙酸乙酯提取物的UPLC-Q-TOF-MS图谱,其条件为:
a.质谱条件为:ESI离子源,正离子模式检测;雾化器N2压力50psi;干燥气N2,流速15L/min;质量扫描范围50--1200;自动3级质谱;
b.色谱分析条件为:色谱柱:Waters ACQUITY UPLC TM BEH C18Column(50mm32.1mm.i d.,1.7μm);二元梯度洗脱,A相为0.1%甲酸水溶液;B相为乙腈,流速为0.35mL/min,梯度洗脱的程序如下:
本发明提供的五倍子的乙酸乙酯提取物具有以下优点:
1、本发明提供了一种五倍子的乙酸乙酯提取物,该提取物是五倍子经过石油醚浸泡,然后渗滤,回收的残渣经过醇提,乙酸乙酯萃取得到的,经过检测,其含有石榴皮鞣素,香草醛,六羟基二苯酰胺葡萄糖,鞣花单宁,杨梅苷,原儿茶素,五倍子单宁倍酰葡萄糖,五倍子单宁,鞣花酸,3,5二咖啡酰奎宁酸,Monogalloyl-glucose、本发明应用超高效液相色谱-质谱联机分析技术及结果构建五倍子提取物图谱的方法。该方法包括五倍子的乙酸乙酯提取物的UPLC-MS分析条件。色谱峰的特征、色谱组分的质谱提供的化合物结果信息等。本发明公开的指纹图谱及其技术可用于五倍子的品种鉴别及五倍子提取物的质量监控。
3、本发明首次提供了五倍子的乙酸乙酯提取物在制备抗EGRF的药物中的应用,经过体外试验,发现本发明提供的五倍子的乙酸乙酯提取物可抑制EGFR,效果明显。
[附图说明]
图1:五倍子的乙酸乙酯提取物的UPLC-Q-TOF-MS正源总离子流图。
[具体实施方式]
为了使本发明的目的、技术方案及优点更加清楚明白,对本发明进行进一步详细说明。本申请中的生产设备都是本领域的常用设备,应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
本发明所使用的石油醚为60-90°的石油醚;
实施例1:
五倍子的乙酸乙酯提取物
五倍子粉碎成粗粉,过35目筛,称取500g五倍子粗粉,然后用1500ml的石油醚浸泡24h,然后用石油醚渗滤,至渗漉液颜色变浅(约收取渗滤液2500ml),回收残渣,挥干残渣中的石油醚,然后用80%乙醇回流提取2次,每次乙醇的用量为2500ml,每次提取时间为2小时,合并提取液,将其减压浓缩至无醇味,然后用与浓缩液等体积的乙酸乙酯萃取,收集上层清液,蒸干得乙酸乙酯提取物85.83g(收率为17.19%)。
实施例2:
五倍子的乙酸乙酯提取物
五倍子粉碎成粗粉,过20目筛,称取500g五倍子粗粉,然后用2500ml的石油醚浸泡48h,然后用石油醚渗漉至渗漉液颜色变浅(约收取渗滤液3000ml),回收残渣,挥干残渣中的石油醚,然后用75%乙醇回流提取2次,每次用2000ml的乙醇,每次提取时间为2小时,合并提取液,然后浓缩至无醇味,然后用与浓缩液等体积的乙酸乙酯萃取,收集上层清液,蒸干得乙酸乙酯提取物143.05g(收率为28.64%)。
实施例3:
五倍子的乙酸乙酯提取物
五倍子粉碎成粗粉,过25目筛,称取500g五倍子粗粉,然后用2000ml的石油醚浸泡24h,然后用石油醚渗漉,至渗漉液颜色变浅(约收取渗滤液5000ml),回收残渣,挥干残渣中的石油醚,然后用70%的乙醇回流提取2次,每次用1500ml的乙醇,每次提取时间为2小时,合并提取液,然后浓缩至无醇味,然后用与浓缩液等体积的乙酸乙酯萃取,收集上层清液,蒸干得乙酸乙酯提取物114.44g(收率为22.92%)。
实施例4:
五倍子的乙酸乙酯提取物
五倍子粉碎成粗粉,过30目筛,称取500g五倍子粗粉,然后用2500ml的石油醚浸泡36h,然后用石油醚渗漉,至渗漉液颜色变浅(约收取渗滤液3500ml),回收残渣,挥干残渣中的石油醚,然后用90%乙醇回流提取2次,每次用2500ml的乙醇,每次提取时间为2小时,合并提取液,然后浓缩至无醇味,然后用与浓缩液等体积的乙酸乙酯萃取,收集上层清液,蒸干得乙酸乙酯提取物108.5g(收率为20.37%)。
实施例5:
五倍子的乙酸乙酯提取物
五倍子粉碎成粗粉,过20目筛,称取500g五倍子粗粉,然后用2000ml的石油醚浸泡48h,然后用石油醚渗漉,至渗漉液颜色变浅(约收取渗滤液3000ml),回收残渣,挥干残渣中的石油醚,然后用60%乙醇回流提取2次,每次用2000ml的乙醇,每次提取时间为2小时,合并提取液,然后浓缩至无醇味,然后用与浓缩液等体积的乙酸乙酯萃取,收集上层清液,蒸干得乙酸乙酯提取物110.64g(收率为21.85%)。
实施例6:
含五倍子的乙酸乙酯提取物的胶囊
1、组成:五倍子的石油醚提取物(实施例1的方法制备)50g,淀粉15g,硬脂酸镁5g。
2、制备方法:按照配比称取原辅料,混合均匀,分装胶囊。
实施例7:
含五倍子的乙酸乙酯提取物的片剂
1、组成:五倍子的乙醇提取物(实施例2的方法制备)50g,淀粉25g,微晶纤维素20g,硬脂酸镁5g。
2、制备方法:按照配比称取原辅料,混合均匀,分装胶囊。
实施例8:
含五倍子的乙酸乙酯提取物的颗粒剂
1、组成:五倍子的乙酸乙酯提取物(实施例3的方法制备)50g,淀粉15g,微晶纤维素20g,硬脂酸镁6g。
2、制备方法:按照配比称取原辅料,按照等量递加法混合均匀,直接压片。
实验例9:
药效实验
1、实验材料:
EGFR激酶(Invitrogen,USA);HTRF KinEASE-TK(Cisbio,USA);ATP、MgCl2、MnCl2、DTT(国产)。
五倍子的乙酸乙酯提取物溶液:将实施例1制备得到的五倍子乙酸乙酯提取物用蒸馏水溶解,浓度为10ug/mL;
阳性对照药:Staurosporine(十字孢碱),其浓度为10ug/mL。
2、实验分组:
阳性对照组:十字孢碱,浓度为10μg/mL;
实验组:实施例1-5组,浓度为10μg/mL。
3、实验模型:
以384孔板为实验容器每孔加入20μL缓冲液,10μL反应底物,10μLVEGFR-2激酶,10μL ATP。在37℃孵箱中孵育30min。然后,依次加入25μL链激酶素标记的XL-665及25μL EuK标记的抗磷酸化的酪氨酸激酶抗体,室温反应用60min。荧光信号参数设置如下:Em=670nm,Ex1=670nm.Ex2=612nm,lagtime=150s,integration time=500s,gain=150。反应设3复孔,检测时每孔读数10次设阴性对照及空白对照。抑制率计算:抑制率/%=(A标准-A样品)/(A标准-A空白)3100。EGRF对照组用去离子水代替待评价样品,空白对照组用去离子水代替评价样品并且用反应缓冲液代替EGRF。
4、实验结果:见表2,表3
表3:半数抑制浓度IC50LogCon(ug/mL)
表2结果显示:半数抑制浓度越低,其抗体的灵敏度越高,表3中实施例3的IC50为5.528,为五个实例中IC50最小的一种,说明其抗EGFR活性实施例效果较好)。
实验例10:
五倍子的乙酸乙酯提取物超高效液相色谱-四级杆飞行时间质谱联用分析系统(即UPLC-Q-TOF-MS)分析
1、实验部分
1.1试剂与样品
乙腈为色谱纯,美国Fisher公司;
超纯水,实验室ELGA PURELAB Classic-UVF纯水机,英国;
其他试剂均为市售国产分析纯。
1.2样品处理
五倍子粉碎成粗粉,过35目筛,称取500g五倍子粗粉,然后用1500ml的石油醚浸泡24h,用石油醚渗滤至渗漉液颜色变浅(约收取渗滤液2500ml),回收残渣,将残渣挥干石油醚,然后用80%乙醇回流提取2次,每次乙醇的用量为2500ml,每次提取时间为2小时,合并两次醇提液,将其减压浓缩至无醇味,然后用与浓缩液等体积的乙酸乙酯萃取,收集上层提取液,蒸干得乙酸乙酯提取物。
1.3仪器与条件
美国Waters AcquityTM UPLC/Q-TOF Premier;MassL-ynxV4.1工作站。
色谱条件同表1:
质谱条件:ESI离子源,正离子模式检测;雾化器N2压力50psi;干燥气N2,流速15L/min;质量扫描范围50--1200;自动3级质谱。(自动选择最强离子进行源内诱导裂解)。
2、结果与分析:结果见图1和表4
图1为五倍子乙酸乙酯提取物UPLC-Q-TOF-MS总离子流图。
针对图1即五倍子的乙酸乙酯提取物的UPLC-Q-TOF-MS(﹢)分析的总离子流图,分析其色谱峰组分指纹信息,结果见表4:
表4:五倍子乙酸乙酯提取物中活性组分分析
表4内容显示:经查阅中外文献,分析鉴定出五倍子乙酸乙酯提取物中的14个色谱峰,其中11个峰分别代表:峰1为石榴皮鞣素,峰2为香草醛,峰3为六羟基二苯酰胺葡萄糖,峰4为鞣花单宁,峰5为杨梅苷,峰6为原儿茶酸,峰7为五倍子单宁倍酰葡萄糖,峰8为鞣花酸-己糖,峰9为未知成分,峰10为3,5二咖啡酰奎宁酸,峰11为未知成分,峰12为未知成分,峰13为Monogalloyl-glucose,峰14为五倍子鞣质。
结果表明:五倍子的乙酸乙酯提取物含有单宁类化合物,也是抗EGFR活性的主要成分。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (9)
1.一种五倍子的乙酸乙酯提取物的方法,其特征在于该方法由以下步骤组成:
a.将五倍子加入到石油醚中浸泡12~48小时,每100g五倍子需要300~500毫升的石油醚,然后渗滤回收残渣;
b.所述的残渣用浓度为60%~90%的乙醇分2~3次提取,每100克残渣每次需要300~500毫升的乙醇,每次提取的时间是1~3小时,收集得到提取液;
c.所述的提取液进行浓缩得到浓缩液;
d.用与浓缩液等体积的乙酸乙酯对所述的浓缩液进行萃取,收集乙酸乙酯的萃取液;
e.蒸干所述的萃取液得到提取物。
2.如权利要求1所述的五倍子的乙酸乙酯提取物的方法,其特征在于每100g五倍子需要300毫升的石油醚浸泡。
3.如权利要求1所述的五倍子的乙酸乙酯提取物的方法,其特征在于所述的浸泡时间为18~36小时。
4.如权利要求1所述的五倍子的乙酸乙酯提取物的方法,其特征在于所述的乙醇浓度为70~90%。
5.如权利要求1所述的五倍子的乙酸乙酯提取物的方法,其特征在于所述的浸泡时间为24小时,每100克残渣每次需要300毫升的乙醇,所述的乙醇浓度为80%,所述的步骤(b)中的提取次数为2次。
6.一种用权利要求1所述方法提取的五倍子的乙酸乙酯提取物,其特征在于该提取物含有主要成分:石榴皮鞣素,香草醛,六羟基二苯酰胺葡萄糖,鞣花单宁,杨梅苷,原儿茶酸,五倍子单宁倍酰葡萄糖,五倍子单宁,鞣花酸-己糖,3,5-二咖啡酰奎宁酸,Monogalloyl-glucose。
7.一种药物制剂,由权利要求6所述的五倍子的乙酸乙酯提取物和药学上可接受的载体组成。
8.权利要求6所述五倍子的乙酸乙酯提取物在制备抑制EGFR活性药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310680435.0A CN103690567B (zh) | 2012-12-28 | 2013-12-12 | 一种五倍子的乙酸乙酯提取物检测方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210587542 | 2012-12-28 | ||
CN2012105875424 | 2012-12-28 | ||
CN201210587542.4 | 2012-12-28 | ||
CN201310680435.0A CN103690567B (zh) | 2012-12-28 | 2013-12-12 | 一种五倍子的乙酸乙酯提取物检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103690567A true CN103690567A (zh) | 2014-04-02 |
CN103690567B CN103690567B (zh) | 2016-04-27 |
Family
ID=50352338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310680435.0A Expired - Fee Related CN103690567B (zh) | 2012-12-28 | 2013-12-12 | 一种五倍子的乙酸乙酯提取物检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103690567B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198574A (zh) * | 2014-09-24 | 2014-12-10 | 辽宁中医药大学 | 五倍子药材的双重指纹图谱质量控制方法 |
CN107648534A (zh) * | 2016-08-31 | 2018-02-02 | 广州市络捷生物科技有限公司 | 一种口腔美白的中药复方提取物及其制备方法和应用 |
CN109549913A (zh) * | 2017-09-26 | 2019-04-02 | 东莞自然衡健康科技有限公司 | 一种五倍子抗衰抗皱有效组分提取物的制备方法 |
CN112773821A (zh) * | 2021-01-13 | 2021-05-11 | 石河子大学 | 一种五倍子多酚的制备方法及其用途 |
CN114137142A (zh) * | 2021-11-25 | 2022-03-04 | 广西壮族自治区食品药品检验所 | 盐肤木的薄层色谱鉴别方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232866A (zh) * | 1998-04-21 | 1999-10-27 | 李素琼 | 五倍子油脂及其提取方法和制药用途 |
-
2013
- 2013-12-12 CN CN201310680435.0A patent/CN103690567B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232866A (zh) * | 1998-04-21 | 1999-10-27 | 李素琼 | 五倍子油脂及其提取方法和制药用途 |
Non-Patent Citations (3)
Title |
---|
孔琪: "五倍子鞣质的提取及抑制亚硝化反应的初步研究", 《应用科技》 * |
杨怀霞等: "茶叶及诃子等植物提取物的抗氧化作用", 《郑州大学学报(医学版)》 * |
邱华锋等: "五倍子提取物PGG抗癌作用研究进展", 《亚太传统医药》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198574A (zh) * | 2014-09-24 | 2014-12-10 | 辽宁中医药大学 | 五倍子药材的双重指纹图谱质量控制方法 |
CN104198574B (zh) * | 2014-09-24 | 2016-07-06 | 辽宁中医药大学 | 五倍子药材的双重指纹图谱质量控制方法 |
CN107648534A (zh) * | 2016-08-31 | 2018-02-02 | 广州市络捷生物科技有限公司 | 一种口腔美白的中药复方提取物及其制备方法和应用 |
CN109549913A (zh) * | 2017-09-26 | 2019-04-02 | 东莞自然衡健康科技有限公司 | 一种五倍子抗衰抗皱有效组分提取物的制备方法 |
CN112773821A (zh) * | 2021-01-13 | 2021-05-11 | 石河子大学 | 一种五倍子多酚的制备方法及其用途 |
CN114137142A (zh) * | 2021-11-25 | 2022-03-04 | 广西壮族自治区食品药品检验所 | 盐肤木的薄层色谱鉴别方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103690567B (zh) | 2016-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103690567A (zh) | 一种五倍子的乙酸乙酯提取物及其制备、检测方法和用途 | |
Li et al. | A novel sample preparation and on-line HPLC–DAD–MS/MS–BCD analysis for rapid screening and characterization of specific enzyme inhibitors in herbal extracts: Case study of α-glucosidase | |
CN104825463B (zh) | 白肉灵芝提取物的代谢调节及抗缺氧的用途 | |
CN103690883A (zh) | 一种姜黄的乙酸乙酯提取物及其制备、检测方法和用途 | |
CN104258106B (zh) | 一种铁皮石斛有效部位的制备方法 | |
CN103705569A (zh) | 一种鸡血藤的乙酸乙酯提取物及其制备、检测方法和用途 | |
CN108003214A (zh) | 一种从土贝母中提取的皂苷化合物及其方法和应用 | |
CN101433592A (zh) | 含黄腐酚的啤酒花提取物及其制备方法 | |
He et al. | Differentiation of Cuscuta chinensis and Cuscuta australis by HPLC-DAD-MS analysis and HPLC-UV quantitation | |
CN104306427A (zh) | 一种红景天提取物及其应用 | |
CN103690595B (zh) | 一种山豆根的乙酸乙酯提取物及其制备、检测方法和应用 | |
CN104788406A (zh) | 白鲜酚酸b及其制备方法和白鲜酚酸b的用途 | |
CN102093449B (zh) | 一种自决明子中分离制备红镰霉素龙胆二糖苷的方法 | |
CN103705559A (zh) | 一种艾叶的乙酸乙酯提取物及其制备、检测方法和用途 | |
CN115951007B (zh) | 一种俄色果配方颗粒的薄层色谱检测方法 | |
CN102058637B (zh) | 一种黄花败酱浸膏的制备方法 | |
CN103705592A (zh) | 一种枇杷叶的乙醇提取物及其制备、检测方法和用途 | |
CN104910172B (zh) | 五种二苯乙烯三聚体的制备方法及其应用 | |
CN106370766B (zh) | 一种鉴别驴胶补血制剂中白术的方法 | |
Song et al. | Simultaneous quantification of six nonpolar ginsenosides in white ginseng by reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection | |
CN103055191B (zh) | 一种治疗肾炎引起血尿的中药的制备方法及质量检测方法 | |
CN103877170B (zh) | 一种虎杖的乙酸乙酯提取物及其制备方法和应用 | |
Liu | Standardization and identification of minor components of silymarin (MK-001) | |
CN102727593A (zh) | 金荞麦及其提取物在制备降血糖药物及保健食品中的新用途 | |
CN104262448B (zh) | 一种从甘草中提取甘草酸的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160427 |